With all the uncertainty of COVID-19, we hope you are safe and in good health. Ozgene is still here to meet your research needs.

Targeting CBLB as a potential therapeutic approach for disseminated candidiasis.

 Back to publications

2016

Nat Med. 2016 Aug;22(8):906-14. doi: 10.1038/nm.4141. Epub 2016 Jul 18.

Targeting CBLB as a potential therapeutic approach for disseminated candidiasis.

Y Xiao;J Tang;H Guo;Y Zhao;R Tang;S Ouyang;Q Zeng;CA Rappleye;MV Rajaram;LS Schlesinger;L Tao;GD Brown;WY Langdon;BT Li;J Zhang

Ohio State University, Columbus, Ohio, USA. Central South University, Changsha, P.R. China. Guangzhou Medical University, Guangzhou, P.R. China. University of South China, Changsha, P.R. China. University of Aberdeen, Aberdeen, UK. University of Western Australia, Crawley, Western Australia, Australia.

Service type: Knock-in mice

Abstract

Disseminated candidiasis has become one of the leading causes of hospital-acquired blood stream infections with high mobility and mortality. However, the molecular basis of host defense against disseminated candidiasis remains elusive, and treatment options are limited. Here we report that the E3 ubiquitin ligase CBLB directs polyubiquitination of dectin-1 and dectin-2, two key pattern-recognition receptors for sensing Candida albicans, and their downstream kinase SYK, thus inhibiting dectin-1- and dectin-2-mediated innate immune responses. CBLB deficiency or inactivation protects mice from systemic infection with a lethal dose of C. albicans, and deficiency of dectin-1, dectin-2, or both in Cblb(-/-) mice abrogates this protection. Notably, silencing the Cblb gene in vivo protects mice from lethal systemic C. albicans infection. Our data reveal that CBLB is crucial for homeostatic control of innate immune responses mediated by dectin-1 and dectin-2. Our data also indicate that CBLB represents a potential therapeutic target for protection from disseminated candidiasis.

View Publication